Journal: PLoS ONE

Article Title: Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice

doi: 10.1371/journal.pone.0060493

Figure Lengend Snippet: (A) T cell proliferation was determined by analyzing [ 3 H]-thymidine incorporation. Splenocytes from mice on day 42 were stimulated for 36 hours with Ang II-KLH, KLH, Ang II or angiotensinogen (AGT) at a concentration of 10 µg/ml. The stimulation index is expressed as the ratio of stimulation to no stimulation. The data are expressed as the mean stimulation index ± the standard error of the mean per 10 6 splenocytes. * P <0.001 vs. no stimulation. (B) A representative photograph from the ELISPOT assay. The ELISPOT assay detected splenocytes that produced IL-4 and/or IFN-γ? Splenocytes from mice on day 42 were stimulated for 48 hours with 10 µg/ml Ang II-KLH, KLH, Ang II or angiotensinogen (AGT). (C) The quantification of spots in the ELISPOT assay. The data are expressed as the mean number of spots ± SEM per 10 6 splenocytes. * P <0.001 vs. saline. (a,c) The results are from 6 control mice (saline) and 6 experimental mice (1,000 ng Ang II-KLH with adjuvant).

Article Snippet: Briefly, 96-well ELISPOT plates (Millipore, Tokyo, Japan) were coated with anti-mouse IFN-γ or IL-4 antibody, as recommended by the manufacturer (R&D Systems, Tokyo, Japan).

Techniques: Concentration Assay, Enzyme-linked Immunospot, Produced, Saline, Adjuvant

Journal: Oncology reports

Article Title: Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease.

doi: 10.3892/or.2015.4176

Figure Lengend Snippet: Figure 1. Anti-IL-18Rα mAb alleviates aGVHD systemic symptoms in aGVHD mice. aGVHD was induced in irradiated BALB/c mice by BMC transplanta- tion. Ten micrograms of anti-IL-18Rα mAb was administered by intraperitoneal injection to mice in the BS+Ab group, while the BS group received injection of PBS. (A) Hunch posture, hair loss and skin lesions were evaluated on day 14 P.T. (B) Changes in body weight of the recipient mice at different time‑points in the different groups. (C) aGVHD clinical scores of the BS+Ab and BS groups on day 14 P.T. (D) Survival rates of aGVHD mice in the different groups. n=6 in each group. *P<0.05. GVHD, graft-versus-host disease; IL-18, interleukin-18; aGVHD, acute GVHD; BMC, bone marrow cell; PBS, phosphate-buffered solution; mAb, monoclonal antibody; P.T., post‑transplantation.

Article Snippet: Recipient mice in the BS+Ab group also received 10 μg/mouse intraperitoneal injection of neutralizing mAb against murine IL-18Rα (catalog no. MAB12161; R&D Systems, Minneapolis, MN, uSA) every 2 days.

Techniques: Irradiation, Injection

Journal: Oncology reports

Article Title: Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease.

doi: 10.3892/or.2015.4176

Figure Lengend Snippet: Figure 2. Effect of anti-IL-18Rα mAb administration on Th cell subsets, pro-inflammatory cytokines and histological scores in the aGVHD mice. (A-C) Peripheral blood levels of Th1 (A), Th2 (B) and Th17 (C) cell subsets in the BS+Ab and BS experimental groups were measured by flow cytometry at different time-points. Serum levels of IFN-γ (D), IL-4 (E), IL-17A (F) and IL-6 (H) at different time-points were detected by cytometric bead array, and IL-18 levels (G) were measured by ELISA. (I) Representative H&E staining of the liver and small intestine tissues of the mice in the BS+Ab and BS groups and the normal control group (untreated animals) on day 14 P.T. Magnification, x400. (J) Histological score was measured on day 14 P.T. n=6 in each group, *P<0.05. GVHD, graft-versus-host disease; aGVHD, acute GVHD; mAb, monoclonal antibody; Th, T helper; IL-18, interleukin-18; ELISA, enzyme-linked immunosorbent assay; H&E, hematoxylin and eosin; P.T., post‑transplantation.

Article Snippet: Recipient mice in the BS+Ab group also received 10 μg/mouse intraperitoneal injection of neutralizing mAb against murine IL-18Rα (catalog no. MAB12161; R&D Systems, Minneapolis, MN, uSA) every 2 days.

Techniques: Flow Cytometry, Enzyme-linked Immunosorbent Assay, Staining, Control